Regulation & Industry news
Regulation & Industry
With billions in revenue set to disappear as patents expire, pharmaceutical giants are racing to acquire their way out of trouble. But are there other drivers behind the surge—and how long can the momentum last? 27 July 2026
Regulation & Industry
Generic drug manufacturers face huge penalties if they fail to relocate production to the US within two years, with India among the countries expected to be hardest hit. 23 July 2026
Regulation & Industry
Plans to merge the UK’s standalone science ministry into an expanded business department, coupled with the departure of the Science Minister, mark a change in the country’s approach to science and innovation. 22 July 2026
Regulation & Industry
Blockbuster acquisitions are back, impacting the pharma industry at record pace. As billions flow into breakthrough science, LSIPR’s series explores what’s driving the surge, how today’s deals are done, and where IP comes into the picture. 17 July 2026
Careers
A high-profile hire will co-chair the firm's new office, bringing experience across biotech, therapeutics, genomics, diagnostics, and medical devices. 16 July 2026
Regulation & Industry
An enhanced agreement between the two countries cements existing protections for pharma innovators and is being hailed by the industry as a boost for investment and research. 14 July 2026
MedTech
A report warns that procurement reforms in Mainland China, alongside the rise of open robotics platforms, supply chain disruption and GLP-1 drugs, are challenging existing medtech business models. 3 July 2026
Regulation & Industry
The newly combined transatlantic firm brings together more than 950 partners across 20 countries, uniting leading patent, trade secrets, life sciences, and tech practices. 29 June 2026
Regulation & Industry
Deal is aimed at strengthening German company’s presence across high-growth life sciences markets by adding a portfolio of advanced research and analytical technologies. 26 June 2026
Regulation & Industry
Novartis will work with a US biotech company on new cancer therapies, while Lilly has partnered with a Chinese biopharma firm to develop new medicines. 25 June 2026